ArticleClinical and translational gastroenterology2019

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.

Zuzana Macek Jilkova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.